Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.

NCT07497854 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07497854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07497854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Not yet recruiting
Start date
March 1, 2027
Completion date
August 1, 2030
Enrollment
3,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

migraine with or without aura